Comparative Pharmacology
Head-to-head clinical analysis: LEVO DROMORAN versus OXTELLAR XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVO DROMORAN versus OXTELLAR XR.
LEVO-DROMORAN vs OXTELLAR XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levo-dromoran (levorphanol) is a potent opioid agonist primarily at mu-opioid receptors, with additional agonist activity at kappa and delta opioid receptors. It also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake, contributing to its analgesic effects.
Oxtellar XR (oxcarbazepine) is a prodrug that is converted to its active metabolite, MHD (10,11-dihydro-10-hydroxy-carbazepine). The exact mechanism of action is unknown, but it is thought to stabilize neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting repetitive neuronal firing and reducing the propagation of synaptic impulses.
2 mg orally every 6-8 hours as needed for pain; 2-4 mg intramuscularly or subcutaneously every 6-8 hours; intravenous administration: 1-2 mg slowly (over 2-3 minutes) every 6-8 hours.
Oxcarbazepine extended-release (OXTELLAR XR) adult dosing: 600 mg orally twice daily; initial dose 300 mg twice daily, titrate by 300 mg/day increments weekly; maximum 2400 mg/day.
None Documented
None Documented
Terminal elimination half-life is 15-30 hours (mean 22 hours) in adults; prolonged in hepatic or renal impairment, requiring dose adjustment.
Terminal half-life approximately 20-30 hours in adults; after multiple doses, effective half-life is about 24 hours, allowing once-daily dosing. Steady state reached in 4-5 days.
Primarily renal (approximately 60% as unchanged drug and metabolites); biliary/fecal elimination accounts for about 30%.
Primarily renal (70-80% as unchanged drug and metabolites) and fecal (20-30% via biliary excretion).
Category C
Category C
Opioid Analgesic
Opioid Analgesic